Volume 4, 2011


TH


International Leaders


The preclinical research projects focus on identifying disease mechanisms and biological targets that have the potential to be starting points for successful and commercially viable treatments of these diseases, both major causes of cardiovascular disease and death worldwide.


Atherosclerosis is one of the primary causes of heart disease and stroke and is a frequent cause of death in both men and women in Western societies. All evidence suggests that the incidence of atherosclerosis will increase worldwide as more people develop obesity and diabetes mellitus because of such factors as poor diet, increased body weight and sedentary lifestyle.


for Education, Research and Drug Discovery


The traditional nonsurgical approach to managing coronary artery disease has been through treatment of such risk factors as high blood lipids, high blood pressure, diabetes and obesity. New and innovative approaches that act directly on the disease in the vessel wall to slow, reverse or stabilize the build-up of atherosclerotic plaque could be important, especially when linked to novel biomarkers of vulnerable plaque identification.


Bjorn Wallmark, vice president of CVGI Discovery, AstraZeneca's cardiovascular and gastrointestinal lab, says, “This is an area of high unmet medical need; atherosclerosis is a primary cause of cardiovascular morbidity and mortality. Partnering with the University of Virginia and working together on the complex biology of these diseases increases the potential of delivering new targets and projects.”


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28